Good morning :)
Place Order
Add to Watchlist

Bajaj Healthcare Ltd

BAJAJHCARE Share Price

535.050.08% (+0.45)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹1,688 cr, stock is ranked 1,237

Stock is 4.61x as volatile as Nifty

BAJAJHCARE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹1,688 cr, stock is ranked 1,237

Stock is 4.61x as volatile as Nifty

BAJAJHCARE Performance & Key Metrics

BAJAJHCARE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
42.776.070.16%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.806.510.80%

BAJAJHCARE Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

BAJAJHCARE Company Profile

Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients and formulations, focusing on amino acids and nutritional supplements for healthcare industries.

BAJAJHCARE Similar Stocks (Peers)

Compare with peers Compare with peers 

BAJAJHCARE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.93
37.93
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
PE Ratio
22.84
22.84
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
PE Ratio
60.91
60.91
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
PE Ratio
54.95
54.95
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
PE Ratio
18.55
18.55
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
Compare with Peers

BAJAJHCARE Forecast

BAJAJHCARE Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

BAJAJHCARE

BAJAJHCARE

Income

Balance Sheet

Cash Flow

BAJAJHCARE Income Statement

BAJAJHCARE Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 6.17%, vs industry avg of 10.15%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.17% to 0.13%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 9.36%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue233.04329.18371.14416.54663.89681.33647.39482.11562.01563.13
Raw Materialssubtract131.50215.43245.33268.32377.19409.91393.84264.43463.61464.74
Power & Fuel Costsubtract16.7919.8121.8324.2424.9631.8337.6931.47
Employee Costsubtract19.5721.6524.6228.1834.5541.1142.3243.85
Selling & Administrative Expensessubtract5.685.687.318.0012.9114.8614.8616.21
Operating & Other expensessubtract26.2825.1028.1632.9871.0063.5266.11154.92
Depreciation/Amortizationsubtract11.3511.0811.4112.1216.1217.6417.2127.6227.9227.92
Interest & Other Itemssubtract8.207.738.326.638.3412.7817.6829.7527.9027.91
Taxes & Other Itemssubtract5.877.507.8610.8235.7118.3014.65-2.353.083.08
EPS1.432.752.954.5715.0617.2415.59-30.3613.2914.31
DPS0.000.250.000.001.381.501.001.001.001.00
Payout ratio0.000.090.000.000.090.090.060.080.07

BAJAJHCARE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Jun 27PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

Aug 18PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

BAJAJHCARE Stock Peers

BAJAJHCARE Past Performance & Peer Comparison

BAJAJHCARE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bajaj Healthcare Ltd42.756.070.16%
Sun Pharmaceutical Industries Ltd37.935.720.93%
Cipla Ltd22.843.851.07%
Torrent Pharmaceuticals Ltd60.9115.340.93%

BAJAJHCARE Stock Price Comparison

Compare BAJAJHCARE with any stock or ETF
Compare BAJAJHCARE with any stock or ETF
BAJAJHCARE
Loading...

BAJAJHCARE Holdings

BAJAJHCARE Shareholdings

BAJAJHCARE Promoter Holdings Trend

BAJAJHCARE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

BAJAJHCARE Institutional Holdings Trend

BAJAJHCARE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

BAJAJHCARE Shareholding Pattern

BAJAJHCARE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.19%1.64%0.88%1.05%37.24%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

BAJAJHCARE Shareholding History

BAJAJHCARE Shareholding History

Dec '23MarJunSepDec '24Mar0.74%0.53%0.01%1.07%1.01%1.05%

Mutual Funds Invested in BAJAJHCARE

Mutual Funds Invested in BAJAJHCARE

No mutual funds holding trends are available

Top 1 Mutual Funds holding Bajaj Healthcare Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.5669%1.42%-0.62%33/35 (-12)

Compare 3-month MF holding change on Screener

BAJAJHCARE Insider Trades & Bulk Stock Deals

BAJAJHCARE Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing BAJAJHCARE stock

smallcases containing BAJAJHCARE stock

Looks like this stock is not in any smallcase yet.

BAJAJHCARE Events

BAJAJHCARE Events

BAJAJHCARE Dividend Trend

No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

BAJAJHCARE has shown inconsistent dividend trend over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.70 every year

Dividends

Corp. Actions

Announcements

Legal Orders

BAJAJHCARE Dividend Trend

No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

BAJAJHCARE has shown inconsistent dividend trend over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.70 every year

BAJAJHCARE Upcoming Dividends

BAJAJHCARE Upcoming Dividends

No upcoming dividends are available

BAJAJHCARE Past Dividends

BAJAJHCARE Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 28, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

Cash Dividend

Ex DateEx DateSep 28, 2021

Special
Special | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

BAJAJHCARE Stock News & Opinions

BAJAJHCARE Stock News & Opinions

Spotlight
Bajaj Healthcare slides after WTD Dhananjay Sabaji Hatle resigns

Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. Bajaj Healthcare reported standalone net profit of Rs 11.18 crore in Q4 FY25 as compared with net loss of Rs 29.92 crore posted in Q4 FY24. However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Bajaj Healthcare recommends final dividend

Bajaj Healthcare announced that the Board of Directors of the Company at its meeting held on 26 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Bajaj Healthcare reports turnaround Q4 numbers

However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025. The company reported a profit before tax of Rs 11.72 crore in Q4 FY25, compared to a pre-tax loss of Rs 35.15 crore in the corresponding quarter of the previous year. Total expenses increased by 19.17% YoY to Rs 156.32 crore in Q4 FY25. Cost of material consumed was Rs 100.49 crore (up 98.47% YoY), while employee expenses stood at Rs 15.71 crore (up 47.92% YoY) and finance costs came in at Rs 6.08 crore (up 1.16% YoY) during the period under review. On a full-year basis, the company reported a standalone net profit of Rs 39.50 crore in FY25, as against a net loss of Rs 83.79 crore in FY24. Revenue from operations jumped 14.61% YoY to Rs 542.60 crore in FY25. Meanwhile, the company's board has recommended a final dividend of Rs 1 per equity share for the financial year 2024-25, subject to the approval of the shareholders at the ensuing Annual General Meeting of the company. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. The counter tumbled 7.75% to Rs 555.60 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Bajaj Healthcare reports standalone net profit of Rs 11.18 crore in the March 2025 quarter

Net profit of Bajaj Healthcare reported to Rs 11.18 crore in the quarter ended March 2025 as against net loss of Rs 29.92 crore during the previous quarter ended March 2024. Sales rose 15.36% to Rs 154.47 crore in the quarter ended March 2025 as against Rs 133.90 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 39.50 crore in the year ended March 2025 as against net loss of Rs 83.79 crore during the previous year ended March 2024. Sales rose 14.61% to Rs 542.60 crore in the year ended March 2025 as against Rs 473.42 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales154.47133.90 15 542.60473.42 15 OPM %7.6211.98 -15.1916.11 - PBDT19.2616.48 17 73.9355.27 34 PBT11.739.18 28 46.0127.65 66 NP11.18-29.92 LP 39.50-83.79 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bajaj Healthcare to convene board meeting

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
India Ratings revises rating outlook of Bajaj Healthcare to 'stable'; affirms rating at 'A-

The agency has affirmed the company's short-term rating at 'IND A2+'. India Ratings and Research stated that the outlook revision reflects strong growth in BHL's revenue and profitability in 9MFY25, coupled with the equity infusions during FY25-FY26 through preferential equity share allotment and share warrants, leading to the repayment of debt and funding for capex requirements. India Ratings notes the equity infusions have led to a significant improvement in the company's credit metrics, with its leverage remaining below 2x over the near to medium term. The ratings reflect BHL's improving business mix, led by diversification in higher margin business formulations coupled with revenue emanating from contract development and manufacturing organisation (CDMO) business which has a long term visibility of supplies and profitability. The agency notes although active pharmaceutical ingredient (API) pricing has stabilised, competition from China in its key products will continue to remain a monitorable. As per the management, BHL has backward integration in its large molecules which will offset any further pricing challenges. The agency will monitor the improvement in the working capital cycle and its impact on the credit metrics in the near term. India Ratings further said that a significant increase in the scale of operations and the profitability while improving the gross working capital cycle, resulting in the net leverage reducing below 2.0x, on a sustained basis, could lead to a positive rating action. However, a significant decline in the scale of operations and the EBITDA margins, along with deterioration in the gross working capital cycle, liquidity position and overall credit metrics, with the net leverage remaining above 3.0x, all on a sustained basis, will be negative for the ratings. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara in Gujarat: one manufacturing plant of finished formulations in Vadodara, Gujarat and one manufacturing plants of intermediates in Tarapur, Maharashtra. The scrip shed 0.86% to currently trade at Rs 553.60 on the BSE. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Bajaj Healthcare gains after acquiring WHO-GMP certified firm Genrx Pharma

The acquisition, valued at Rs 10.85 crore through a cash consideration, involves 100% control of Genrx Pharmaceuticals. GenRx Pharmaceuticals is a WHO-GMP certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products. The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays. Anil Jain, managing director, Bajaj Healthcare, said: 'The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth. Completion of the acquisition is expected within 3'6 months, subject to requisite FDA and other regulatory approvals. This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector. Bajaj Healthcare a leading manufacturer of apis, intermediates and formulations. It specializes in manufacturing of intermediates, API, formulations & nutraceuticals. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Bajaj Healthcare reports standalone net profit of Rs 11.72 crore in the December 2024 quarter

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales122.79108.57 13 OPM %17.6217.98 - PBDT18.5013.67 35 PBT11.656.32 84 NP11.72-2.20 LP Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Bajaj Healthcare to table results

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Bajaj Healthcare gets DGCI nod for manufacturing of Pimavanserin in India

Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025. The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market. Anil Jain, managing director, Bajaj Healthcare, said: 'The approval marks a major milestone for Bajaj Healthcare. The growing success of NUPLAZID in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment. This move further solidifies our presence in the central nervous system (CNS) segment and highlights our dedication to advancing healthcare solutions in India.' Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company had reported standalone net profit of Rs 94.64 crore in Q2 FY25 as compared with net loss of Rs 34.60 crore in Q2 FY24. Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25. The scrip fell 2.46% to currently trade at Rs 640.25 on the BSE. Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Bajaj Healthcare Ltd (BAJAJHCARE) today?

    The share price of BAJAJHCARE as on 16th July 2025 is ₹535.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Bajaj Healthcare Ltd (BAJAJHCARE) share?

    The past returns of Bajaj Healthcare Ltd (BAJAJHCARE) share are
    • Past 1 week: 8.94%
    • Past 1 month: -0.03%
    • Past 3 months: -13.98%
    • Past 6 months: 0.10%
    • Past 1 year: 39.97%
    • Past 3 years: 52.44%
    • Past 5 years: 47.29%

  3. What are the peers or stocks similar to Bajaj Healthcare Ltd (BAJAJHCARE)?
  4. What is the dividend yield % of Bajaj Healthcare Ltd (BAJAJHCARE) share?

    The current dividend yield of Bajaj Healthcare Ltd (BAJAJHCARE) is 0.16.

  5. What is the market cap of Bajaj Healthcare Ltd (BAJAJHCARE) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bajaj Healthcare Ltd (BAJAJHCARE) is ₹1688.45 Cr as of 16th July 2025.

  6. What is the 52 week high and low of Bajaj Healthcare Ltd (BAJAJHCARE) share?

    The 52-week high of Bajaj Healthcare Ltd (BAJAJHCARE) is ₹745 and the 52-week low is ₹330.90.

  7. What is the PE and PB ratio of Bajaj Healthcare Ltd (BAJAJHCARE) stock?

    The P/E (price-to-earnings) ratio of Bajaj Healthcare Ltd (BAJAJHCARE) is 42.75. The P/B (price-to-book) ratio is 6.07.

  8. Which sector does Bajaj Healthcare Ltd (BAJAJHCARE) belong to?

    Bajaj Healthcare Ltd (BAJAJHCARE) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Bajaj Healthcare Ltd (BAJAJHCARE) shares?

    You can directly buy Bajaj Healthcare Ltd (BAJAJHCARE) shares on Tickertape. Simply sign up, connect your demat account and place your order.